Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities (2016 - 2026)

Agios Pharmaceuticals (AGIO) has disclosed Cash from Financing Activities for 15 consecutive years, with $2.1 million as the latest value for Q1 2026.

  • For Q1 2026, Cash from Financing Activities rose 28.35% year-over-year to $2.1 million; the TTM value through Mar 2026 reached $9.1 million, down 10.41%, while the annual FY2025 figure was $8.7 million, 39.93% down from the prior year.
  • Cash from Financing Activities hit $2.1 million in Q1 2026 for Agios Pharmaceuticals, down from $2.6 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $5.9 million in Q1 2024 and bottomed at -$67000.0 in Q2 2022.
  • Average Cash from Financing Activities over 5 years is $1.9 million, with a median of $1.6 million recorded in 2025.
  • Year-over-year, Cash from Financing Activities soared 3750.0% in 2023 and then tumbled 94.09% in 2025.
  • Agios Pharmaceuticals' Cash from Financing Activities stood at $22000.0 in 2022, then skyrocketed by 3750.0% to $847000.0 in 2023, then soared by 471.66% to $4.8 million in 2024, then tumbled by 47.19% to $2.6 million in 2025, then dropped by 18.73% to $2.1 million in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods came in at $2.1 million, $2.6 million, and $4.4 million for Q1 2026, Q4 2025, and Q3 2025 respectively.